Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively managed ETF that seeks current income while providing indirect inverse exposure to the share price (i.e., the price returns) of the common stock of Nvidia Corporation. Its potential for gains from decreases in the share price of NVDA’s stock is limited. The fund is non-diversified.

Dragon_Trader_66
Dragon_Trader_66 Oct. 22 at 2:12 PM
$CONY I sold all positions in the $NVDY & $DIPS holdings after Yieldmax posted their weekly dividends for these pieces of shit ETFs. They are paying out well under half of what the other inverted pairs are paying so I'll realign tomorrow at the dividend dips in the others. I'm also going to spend some research time looking around at some other hi-yield dividend paying companies to see if it might be more beneficial to invest elsewhere. I also sold out of $QDTY & $YQQQ positions entirely for the same reasons. These two combined are paying less than one quarter of what the other inverted pairs are paying. No need to wait for the dividends in any of these 4 ETF's because they are entire a waste of investment capital. I said it last week and I still say it, Yieldmax may not be worth holding any of their funds much longer. The 4 that I eliminated were a complete waste of investment capital. I'll will use it elsewhere since Yieldmax does not seem to need my business any longer.
4 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 22 at 2:03 PM
$NVDY I sold my positions in the $NVDY & $DIPS holdings after Yieldmax posted their weekly dividends for these pieces of shit. They are paying out well under half of what the other inverted pairs are paying so I'll align there tomorrow at the dividend dips in the others. I'm also going to spend some research time looking around at some other hi-yield dividend paying companies to see if it might simply be more beneficial to invest elsewhere. I also sold out of $QDTY & $YQQQ positions entirely for the exact same reasons. These two combined are paying less than one quarter of what the other inverted pairs are paying. No need to wait for the dividends in any of these 4 ETF's because they are entire a waste of investment capital. I said it last week and I still say it, Yieldmax may not be worth holding any of their funds much longer. The 4 that I eliminated were a complete waste of investment capital. I'll simply use it elsewhere since Yieldmax does not seem to need my business any longer.
0 · Reply
Investogainerresearch
Investogainerresearch Oct. 19 at 5:03 PM
$LAURUSLABS.NSE जहाँ विज्ञान है जीवन की सेवा में, वहाँ होता है स्वस्थ भविष्य का निर्माण – Laurus Labs के साथ आप हमेशा सुरक्षित! Company Overview $LAURUS Labs is a Hyderabad-based integrated pharmaceutical and biotechnology company, established in 2005. The business is built on three pillars: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Custom Synthesis/CDMO. Laurus commands leadership in anti-retroviral, oncology, and specialty APIs, supplying to over 70 countries, with 15 globally approved manufacturing facilities. Their portfolio increasingly emphasizes advanced biotech, gene therapy, and specialty chemistry innovation, making the business future-ready for high-margin science-driven expansion. Financial Performance & Quality •FY25 Revenues: ₹5,554 Crore (YoY growth 10%). •Q1 FY26 Revenues: ₹1,580 Crore, 32% YoY growth, indicating robust operational scaling. •FY25 Net Profit: ₹358 Crore (up 122% YoY; net margin 6.4%). •Q1 FY26 PAT: ₹161.68 Crore, up 1175% YoY, with EPS at ₹3.0. •EBITDA (FY25): ₹1,115 Crore (+40% YoY); EBITDA Margin: 20.1% (up 430 bps YoY), supported by improved product mix & asset utilization. •ROCE: 9.7%, up 330 bps YoY; ROE: 11%. •R&D Spend: ₹257 Crore (4.6% of revenue), reflecting future-ready innovation; 75+ new projects and peptide, gene therapy diversification. •Net Debt/EBITDA: 2.3x (improving leverage); Capex: ₹659 Crore FY25; operating cash slightly declined on higher working capital. •Valuation: P/E 96x TTM, P/B 10.9, P/S 8.19 – at premium, justified if growth/innovation persists. Business Drivers & Expansion •$STRONG performance in the Custom Synthesis/CDMO vertical with growing global contracts. •ARV business stable; focus on scaling specialty APIs, gene, and cell therapies. •Strategically deepening$ $RELATIONSHIPS with global innovators and investing in peptide chemistry, biocatalysis, and continuous flow tech. •JV with Slovenia’s KRKA, new R&D sites, peptide launch & expanded European presence indicate sustained global vision. Technical Analysis (Oct 2025) •CMP: ₹900.05 •The $STOCK is showing momentum recovery after previous consolidation; recent price breakout above moving averages (green/cyan/blue/black/gold lines) confirms bullish undertone. •Parabolic SAR: Flipped below price – bullish indicator. •MACD: Crossed positive with rising histogram, suggesting fresh upward power. •RSI(14): At 59, healthy but not yet overbought, signaling trend strength. •Support: ₹865–₹870 first zone, ₹840 strong base; Resistance: ₹915–₹940 immediate, ₹955–₹970 stretch targets. •Volume and sentiment favor buyers; if ₹870 sustains, structure is positive, otherwise risk of pullback increases. Result Trend & Future Outlook •Q1 & Q2 FY26 results reflect a sharp rebound in profit and margin expansion, led by operational leverage and specialty pipeline. •Management is targeting 50% $REVENUE share from high-margin CDMO and innovative therapies by 2027; capex guidance indicates aggressive scaling. •Improved mix, operational efficiency, and asset utilization raise FY27E margin/income projections, but premium valuation requires sustained delivery. •Near term, any new international contract/joint venture or USFDA approval can act as sentiment boosters; conversely, adverse regulatory/currency moves could trigger volatility. Entry, Target, and Risk Management •Buy on $DIPS between ₹870–₹900, keeping a closing stop loss at ₹840. •Short-term targets: ₹915 & ₹940. On breakout and strength, look for ₹955–₹970. •$LONG-term holders may use corrections to accumulate, subject to fundamental strength and macro cues. •The uptrend will be valid as long as ₹870 support holds; break below this can invite profit booking. Risks & Upcoming Events •Sustained performance in CDMO/biotech and regulatory approvals are key. •Any delay in global orders, $NEGATIVE audit outcomes, or unfavorable currency/cost swings are key watchpoints. •Multiple R&D pipeline events and global launches ahead. Result Announcement & its Impact: $LAURUSLABS.NSE Labs will be announcing its quarterly financial results on 23rd October 2025. This result will be closely watched by investors and analysts for updates on revenue growth, margin expansion, new product launches, and any management commentary regarding future outlook, pipeline progress, and global contracts. Key Impact for Investors: •The upcoming result will indicate how $LAURUS Labs is executing on its specialty API and CDMO expansion, as well as whether recent margin and profit growth trends are being sustained. •Short-term price volatility is expected around the result date, especially if reported numbers differ from market earnings forecasts. •Positive surprises on earnings, margins, or new contracts could support fresh upside, while disappointments could trigger correction or profit booking. This scheduled result is a $CRITICAL event and could dictate the next leg of price movement for Laurus Labs—remain updated for the 23rd October earnings release and assess entry/exit moves accordingly. Disclaimer & Disclosure This content is for informational/educational purposes only and does not constitute investment or trading advice. Investing in securities carries risk; always consult your SEBI-registered advisor. Neither author nor Investogainer Research hold any position in Laurus Labs.
0 · Reply
ZarathustraTao
ZarathustraTao Oct. 12 at 6:23 PM
$WNTR $CRSH $FIAT $DIPS these were great at helping during these times, always have balance.
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 10 at 2:09 PM
$NVDY Let the Friday rebalancing begin....LOL. ;-) Added to both $NVDY and $MSTY to bring their averages back to the 12.5% balance. At the same time, I sold a small amount of $CONY yesterday afternoon to take some profit and help finance these buys today along with the dividends paid into the account. I even picked up 4000 shares of the trash can penny popper IBOGF since it was so cheap this morning. Next ETFs of the 8 I'll be forced to address early next week looks to be both $FIAT & $DIPS. But we will see come next week. Rebalance is complete for this week. Nothing but a thing!
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 9 at 1:51 PM
$NVDY I have a penny stock (IBOGF) that I always add my spare change from trades I call the "Trash Can". It is not currently listed on Stocktwits yet. $NVDA & $DIPS But...Universal Ibogaine (IBOGF) plans to file a Clinical Trial Application with Health Canada within 90 days, targeting opioid use disorder. Also, in Texas, a state-funded "ibogaine" trial initiative is underway, backed by $50M and focused on PTSD and addiction, especially among veterans. 🇨🇦 Canada: Universal Ibogaine’s Clinical Trial Application • Company: Universal Ibogaine Inc. (TSXV: IBO, OTC: IBOGF) • Announcement Date: September 4, 2025 • Trial Focus: Investigating ibogaine as a treatment for opioid use disorder • Status: Preparing to file a Clinical Trial Application (CTA) with Health Canada within 90 days. • Drug Supply: Secured pharmaceutical-grade ibogaine produced under GMP standards • Facility: Kelburn Recovery Centre near Winnipeg, Manitoba—intended to pair holistic addiction treatment with ibogaine.
2 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 7 at 2:26 PM
$NVDY NVDY and DIPS are both paying dividends this week (ex-date: Oct 9), but NVDA’s bullish momentum and options volatility are driving asymmetric pressure on their share prices. $NVDY benefits from $NVDA’s surge; $DIPS faces headwinds. Options expiry on Oct 10 adds fuel to the volatility overlay. I'm always bullish on weeks these inverted ETFs pay out their dividends to me. ;-) 🧾 Dividend Snapshot (Week of Oct 7–11) • NVDY (YieldMax NVDA Option Income Strategy ETF) • Ex-dividend date: Oct 9, 2025 • Projected dividend: $0.6428 • Trailing 12-month yield: ~66.8% • Price: $16.95 (+1.53%) • DIPS (YieldMax Short NVDA Option Income Strategy ETF) • Ex-dividend date: Oct 9, 2025 • Projected dividend: $0.287 • Trailing 12-month yield: ~91.2% • Price: $5.92 (+1.20%)
1 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 3 at 1:53 PM
$TSLY Good morning...(using an appropriate greeting) to all. Today, had to rebalance the 8 hi-yield dividend paying funds early at the market open due to thing that have come up. Would normally have waited until later after 2:00 PM, but it's done. Done commenting on $TSLY and $CRSH for a while since that money has been applied in the rebalancing scheme. Next week comes the $NVDY & $DIPS dividends to apply across the board whatever they may be paying. It's all about the 12.5% for the 8 ETF's and I can't get any closer today than where I am. I dumped the remaining spare change into my favorite and only trash can penny stock "IBOGF". You never heard of it. That's why it's the trash can....until it isn't! LMAO Good day everyone!
1 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 2 at 2:54 PM
$CRSH As some who follow me know, I hold all 8 of the Yieldmax Inverted hi-yield ETFs (CONY & FIAT, NVDY& DIPS, TSLY & CRSH, and MSTY & WNTR). The rebalance back to 12.5% in each holding will happen tomorrow sometime after 2:00PM to give those options traders the time they need to adjust their holding due to the expiring options. I know exactly how much I'll receive in dividends tomorrow; I added my bi-monthly tranche of new funds for this rebalance, and I took some profit this morning on NVDY, MSTY, TSLY and CONY. My rebalance is set in stone now so I just have to wait for tomorrow's action. I'll definitely be buying just enough into $FIAT, $DIPS, $CRSH & $WNTR to bring them back up to 12.5% each from my cash reserves. I simply buy low - sell high each week based off those percentages. New week, same philosophy every week. And yes...I will make money once again with more shares to go around to build the portfolio.
0 · Reply
ZarathustraTao
ZarathustraTao Sep. 18 at 11:17 PM
$WNTR $DIPS $CRASH $FIAT also getting paid on the downside, 10 year bull run is gonna be nice.
2 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 22 at 2:12 PM
$CONY I sold all positions in the $NVDY & $DIPS holdings after Yieldmax posted their weekly dividends for these pieces of shit ETFs. They are paying out well under half of what the other inverted pairs are paying so I'll realign tomorrow at the dividend dips in the others. I'm also going to spend some research time looking around at some other hi-yield dividend paying companies to see if it might be more beneficial to invest elsewhere. I also sold out of $QDTY & $YQQQ positions entirely for the same reasons. These two combined are paying less than one quarter of what the other inverted pairs are paying. No need to wait for the dividends in any of these 4 ETF's because they are entire a waste of investment capital. I said it last week and I still say it, Yieldmax may not be worth holding any of their funds much longer. The 4 that I eliminated were a complete waste of investment capital. I'll will use it elsewhere since Yieldmax does not seem to need my business any longer.
4 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 22 at 2:03 PM
$NVDY I sold my positions in the $NVDY & $DIPS holdings after Yieldmax posted their weekly dividends for these pieces of shit. They are paying out well under half of what the other inverted pairs are paying so I'll align there tomorrow at the dividend dips in the others. I'm also going to spend some research time looking around at some other hi-yield dividend paying companies to see if it might simply be more beneficial to invest elsewhere. I also sold out of $QDTY & $YQQQ positions entirely for the exact same reasons. These two combined are paying less than one quarter of what the other inverted pairs are paying. No need to wait for the dividends in any of these 4 ETF's because they are entire a waste of investment capital. I said it last week and I still say it, Yieldmax may not be worth holding any of their funds much longer. The 4 that I eliminated were a complete waste of investment capital. I'll simply use it elsewhere since Yieldmax does not seem to need my business any longer.
0 · Reply
Investogainerresearch
Investogainerresearch Oct. 19 at 5:03 PM
$LAURUSLABS.NSE जहाँ विज्ञान है जीवन की सेवा में, वहाँ होता है स्वस्थ भविष्य का निर्माण – Laurus Labs के साथ आप हमेशा सुरक्षित! Company Overview $LAURUS Labs is a Hyderabad-based integrated pharmaceutical and biotechnology company, established in 2005. The business is built on three pillars: Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and Custom Synthesis/CDMO. Laurus commands leadership in anti-retroviral, oncology, and specialty APIs, supplying to over 70 countries, with 15 globally approved manufacturing facilities. Their portfolio increasingly emphasizes advanced biotech, gene therapy, and specialty chemistry innovation, making the business future-ready for high-margin science-driven expansion. Financial Performance & Quality •FY25 Revenues: ₹5,554 Crore (YoY growth 10%). •Q1 FY26 Revenues: ₹1,580 Crore, 32% YoY growth, indicating robust operational scaling. •FY25 Net Profit: ₹358 Crore (up 122% YoY; net margin 6.4%). •Q1 FY26 PAT: ₹161.68 Crore, up 1175% YoY, with EPS at ₹3.0. •EBITDA (FY25): ₹1,115 Crore (+40% YoY); EBITDA Margin: 20.1% (up 430 bps YoY), supported by improved product mix & asset utilization. •ROCE: 9.7%, up 330 bps YoY; ROE: 11%. •R&D Spend: ₹257 Crore (4.6% of revenue), reflecting future-ready innovation; 75+ new projects and peptide, gene therapy diversification. •Net Debt/EBITDA: 2.3x (improving leverage); Capex: ₹659 Crore FY25; operating cash slightly declined on higher working capital. •Valuation: P/E 96x TTM, P/B 10.9, P/S 8.19 – at premium, justified if growth/innovation persists. Business Drivers & Expansion •$STRONG performance in the Custom Synthesis/CDMO vertical with growing global contracts. •ARV business stable; focus on scaling specialty APIs, gene, and cell therapies. •Strategically deepening$ $RELATIONSHIPS with global innovators and investing in peptide chemistry, biocatalysis, and continuous flow tech. •JV with Slovenia’s KRKA, new R&D sites, peptide launch & expanded European presence indicate sustained global vision. Technical Analysis (Oct 2025) •CMP: ₹900.05 •The $STOCK is showing momentum recovery after previous consolidation; recent price breakout above moving averages (green/cyan/blue/black/gold lines) confirms bullish undertone. •Parabolic SAR: Flipped below price – bullish indicator. •MACD: Crossed positive with rising histogram, suggesting fresh upward power. •RSI(14): At 59, healthy but not yet overbought, signaling trend strength. •Support: ₹865–₹870 first zone, ₹840 strong base; Resistance: ₹915–₹940 immediate, ₹955–₹970 stretch targets. •Volume and sentiment favor buyers; if ₹870 sustains, structure is positive, otherwise risk of pullback increases. Result Trend & Future Outlook •Q1 & Q2 FY26 results reflect a sharp rebound in profit and margin expansion, led by operational leverage and specialty pipeline. •Management is targeting 50% $REVENUE share from high-margin CDMO and innovative therapies by 2027; capex guidance indicates aggressive scaling. •Improved mix, operational efficiency, and asset utilization raise FY27E margin/income projections, but premium valuation requires sustained delivery. •Near term, any new international contract/joint venture or USFDA approval can act as sentiment boosters; conversely, adverse regulatory/currency moves could trigger volatility. Entry, Target, and Risk Management •Buy on $DIPS between ₹870–₹900, keeping a closing stop loss at ₹840. •Short-term targets: ₹915 & ₹940. On breakout and strength, look for ₹955–₹970. •$LONG-term holders may use corrections to accumulate, subject to fundamental strength and macro cues. •The uptrend will be valid as long as ₹870 support holds; break below this can invite profit booking. Risks & Upcoming Events •Sustained performance in CDMO/biotech and regulatory approvals are key. •Any delay in global orders, $NEGATIVE audit outcomes, or unfavorable currency/cost swings are key watchpoints. •Multiple R&D pipeline events and global launches ahead. Result Announcement & its Impact: $LAURUSLABS.NSE Labs will be announcing its quarterly financial results on 23rd October 2025. This result will be closely watched by investors and analysts for updates on revenue growth, margin expansion, new product launches, and any management commentary regarding future outlook, pipeline progress, and global contracts. Key Impact for Investors: •The upcoming result will indicate how $LAURUS Labs is executing on its specialty API and CDMO expansion, as well as whether recent margin and profit growth trends are being sustained. •Short-term price volatility is expected around the result date, especially if reported numbers differ from market earnings forecasts. •Positive surprises on earnings, margins, or new contracts could support fresh upside, while disappointments could trigger correction or profit booking. This scheduled result is a $CRITICAL event and could dictate the next leg of price movement for Laurus Labs—remain updated for the 23rd October earnings release and assess entry/exit moves accordingly. Disclaimer & Disclosure This content is for informational/educational purposes only and does not constitute investment or trading advice. Investing in securities carries risk; always consult your SEBI-registered advisor. Neither author nor Investogainer Research hold any position in Laurus Labs.
0 · Reply
ZarathustraTao
ZarathustraTao Oct. 12 at 6:23 PM
$WNTR $CRSH $FIAT $DIPS these were great at helping during these times, always have balance.
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 10 at 2:09 PM
$NVDY Let the Friday rebalancing begin....LOL. ;-) Added to both $NVDY and $MSTY to bring their averages back to the 12.5% balance. At the same time, I sold a small amount of $CONY yesterday afternoon to take some profit and help finance these buys today along with the dividends paid into the account. I even picked up 4000 shares of the trash can penny popper IBOGF since it was so cheap this morning. Next ETFs of the 8 I'll be forced to address early next week looks to be both $FIAT & $DIPS. But we will see come next week. Rebalance is complete for this week. Nothing but a thing!
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 9 at 1:51 PM
$NVDY I have a penny stock (IBOGF) that I always add my spare change from trades I call the "Trash Can". It is not currently listed on Stocktwits yet. $NVDA & $DIPS But...Universal Ibogaine (IBOGF) plans to file a Clinical Trial Application with Health Canada within 90 days, targeting opioid use disorder. Also, in Texas, a state-funded "ibogaine" trial initiative is underway, backed by $50M and focused on PTSD and addiction, especially among veterans. 🇨🇦 Canada: Universal Ibogaine’s Clinical Trial Application • Company: Universal Ibogaine Inc. (TSXV: IBO, OTC: IBOGF) • Announcement Date: September 4, 2025 • Trial Focus: Investigating ibogaine as a treatment for opioid use disorder • Status: Preparing to file a Clinical Trial Application (CTA) with Health Canada within 90 days. • Drug Supply: Secured pharmaceutical-grade ibogaine produced under GMP standards • Facility: Kelburn Recovery Centre near Winnipeg, Manitoba—intended to pair holistic addiction treatment with ibogaine.
2 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 7 at 2:26 PM
$NVDY NVDY and DIPS are both paying dividends this week (ex-date: Oct 9), but NVDA’s bullish momentum and options volatility are driving asymmetric pressure on their share prices. $NVDY benefits from $NVDA’s surge; $DIPS faces headwinds. Options expiry on Oct 10 adds fuel to the volatility overlay. I'm always bullish on weeks these inverted ETFs pay out their dividends to me. ;-) 🧾 Dividend Snapshot (Week of Oct 7–11) • NVDY (YieldMax NVDA Option Income Strategy ETF) • Ex-dividend date: Oct 9, 2025 • Projected dividend: $0.6428 • Trailing 12-month yield: ~66.8% • Price: $16.95 (+1.53%) • DIPS (YieldMax Short NVDA Option Income Strategy ETF) • Ex-dividend date: Oct 9, 2025 • Projected dividend: $0.287 • Trailing 12-month yield: ~91.2% • Price: $5.92 (+1.20%)
1 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 3 at 1:53 PM
$TSLY Good morning...(using an appropriate greeting) to all. Today, had to rebalance the 8 hi-yield dividend paying funds early at the market open due to thing that have come up. Would normally have waited until later after 2:00 PM, but it's done. Done commenting on $TSLY and $CRSH for a while since that money has been applied in the rebalancing scheme. Next week comes the $NVDY & $DIPS dividends to apply across the board whatever they may be paying. It's all about the 12.5% for the 8 ETF's and I can't get any closer today than where I am. I dumped the remaining spare change into my favorite and only trash can penny stock "IBOGF". You never heard of it. That's why it's the trash can....until it isn't! LMAO Good day everyone!
1 · Reply
Dragon_Trader_66
Dragon_Trader_66 Oct. 2 at 2:54 PM
$CRSH As some who follow me know, I hold all 8 of the Yieldmax Inverted hi-yield ETFs (CONY & FIAT, NVDY& DIPS, TSLY & CRSH, and MSTY & WNTR). The rebalance back to 12.5% in each holding will happen tomorrow sometime after 2:00PM to give those options traders the time they need to adjust their holding due to the expiring options. I know exactly how much I'll receive in dividends tomorrow; I added my bi-monthly tranche of new funds for this rebalance, and I took some profit this morning on NVDY, MSTY, TSLY and CONY. My rebalance is set in stone now so I just have to wait for tomorrow's action. I'll definitely be buying just enough into $FIAT, $DIPS, $CRSH & $WNTR to bring them back up to 12.5% each from my cash reserves. I simply buy low - sell high each week based off those percentages. New week, same philosophy every week. And yes...I will make money once again with more shares to go around to build the portfolio.
0 · Reply
ZarathustraTao
ZarathustraTao Sep. 18 at 11:17 PM
$WNTR $DIPS $CRASH $FIAT also getting paid on the downside, 10 year bull run is gonna be nice.
2 · Reply
sonofaperch
sonofaperch Sep. 6 at 2:12 AM
$SMCY Sold all my shares of $SMCY and will re-enter before next XDIV date, bought some $DIPS, $GPTY and added some to my positions of $PLTY and $BABO. GLTA
0 · Reply
superstocking
superstocking Aug. 20 at 3:22 PM
$MRNY $DIPS $GDXY $LGFY Some YieldMax ETF outperforming predictions (sorry $MRNY it was better yesterday) etfcatpure.com
0 · Reply
sonofaperch
sonofaperch Aug. 14 at 3:29 AM
$BABO got rid of my losers today, $FIAT $DIPS $CRSH and put the proceeds back to work into $BABO.
0 · Reply
Daschle
Daschle Aug. 9 at 10:21 PM
$DIPS I started a small investing earlier this week. I’ll be watching to see if this stock starts taking off to see if I’m going to add more
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Aug. 8 at 2:19 PM
$DIPS I have a feeling that at some point the one or some of powers that will be taking a big bite out of the $DIPS current pricing range. Just a hunch really. I'm equally positioned in both $DIPS & $NVDY. On the other hand, $NVDY is running strong and does 20X the volume alone. The Ex-Dividend date for both is next Thursday. I wonder which fund will have the greatest momentum next week. Should be interesting.
1 · Reply
Dragon_Trader_66
Dragon_Trader_66 Aug. 7 at 3:04 PM
$NVDY Today, I've added to positions in both $NVDY and $DIPS. Their next dividend payouts will be upon us next week, so just getting started early. There's a sense of balance with these inverted funds. Ever wonder about that? ;-)
0 · Reply
Akris
Akris Jul. 30 at 5:14 PM
$DIPS Yay! I sold all my DIPS/hit!
0 · Reply
Investogainerresearch
Investogainerresearch Jul. 22 at 9:33 AM
$INFY.NSE Fundamental View- $INFOSYS Ltd. is one of India’s leading IT services and consulting companies, known for its global presence, strong corporate governance, and consistent financial performance. It provides a wide range of services including digital transformation, cloud computing, AI, enterprise application services, and business process management. As of FY24, the $COMPANY reported revenue of ₹1.56 lakh crore and a net profit of around ₹26,200 crore, maintaining healthy margins and strong cash reserves. Infosys maintains a high return on equity (ROE) of over 30% and a debt-free balance sheet, which adds to its financial stability. The $COMPANY’s order book remains strong, with a solid pipeline in digital and automation services, particularly from North America and Europe. With a dividend-paying track record and leadership in the IT sector, Infosys continues to be a favourite among long-term investors. Technical View- Based on the daily chart, $INFOSYS (INFY) is currently showing technical weakness ahead of its Q1 results scheduled for 23 July. The $STOCK has broken below its short-term moving averages, with Parabolic SAR dots appearing above the price and a negative MACD crossover confirming a loss of momentum. The RSI at 41.15 indicates declining strength, though it hasn’t entered oversold territory yet. Macroeconomic uncertainty — particularly from the US and BFSI sectors — continues to weigh on large-cap IT companies, including Infosys. While the $COMPANY has attempted to protect margins through cost optimization and large deal wins, muted top-line growth remains a concern. On the positive side, stable margins, a strong deal pipeline, and $CURRENCY tailwinds (INR depreciation) may offer some support. The price action reflects a lower-high, lower-low structure, suggesting a short-term downtrend. A breakdown below ₹1580 could lead to further downside towards ₹1550–1540, while the ₹1600–1610 zone now acts as immediate resistance. With earnings due tomorrow, traders should expect volatility, and a decisive view will likely emerge post-results. Long-term investors may consider accumulating on $DIPS, but fresh entries are best timed after clarity from Q1 performance. Warning- https://investogainerresearch.com/disclaimer https://investogainerresearch.com/standarddisclouser
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Jul. 18 at 2:08 PM
In keeping with maintaining in 12.5% my portfolio of the 8 inverted hi-yield Yieldmax funds with the dividends received this week, I have added to both $CONY & $FIAT. I have also added to $DIPS & $CRSH. CONY and FIAT were no-brainers as they have upcoming dividends next week, but I had to bring both DIPS and CRSH back up to the 12.5% threshold also. Hard work for a Friday. Have a great weekend everyone. Myself, I'll be chasing a couple grandkids and some of their friends around tubing on the lake.
1 · Reply
Dragon_Trader_66
Dragon_Trader_66 Jul. 17 at 6:04 PM
$DIPS Here is my current watchlist and the only funds I am invested in with this particular portfolio. These are the 8 funds that are all inverted to each other. I simply track them by keeping them each at 12.5% of the portfolio. I do not DRIP my dividends because I use the weekly payout to maintain equal percentages and simply let the price movements each week determine which fund or funds to add to. Works for me. This week the NVDY and DIPS funds will be used to rebalance everything again tomorrow. Done for this day. GL to you all!
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Jul. 17 at 2:03 PM
$NVDY Probably won't be able to get $NVDY this cheap again for a while. I added to it as planned right at the open. Added some yesterday for tomorrows dividends, added a little more today just because I wanted more shares cheaper for the future. I'm watching $DIPS also...but no changes there in my holdings for the time being. Tomorrow, the money from those that DRIP back into $NVDY will be hitting so I'm expecting a volume push upward on today's pricing. But JMHO...what do I know! ;-)
0 · Reply
Dragon_Trader_66
Dragon_Trader_66 Jul. 16 at 2:33 PM
I can't argue looking a gift horse in the mouth. So, I have definitely added to $NVDY with a share price at 17.75 this morning bringing a dividend or $1.0285 just to capture the dividends tomorrow. Why not.... right! Sad looking at $DIPS and that measly lil $0.1716 dividend with a share price at $7.04. $DIPS share price is right around 2 and a half that less than $NVDY but that dividend is about 6X less. Strange math.
0 · Reply